+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating how well the medicine zasocitinib works and its safety in children and teenagers aged 4 to under 18 with moderate-to-severe plaque psoriasis. The study is conducted in two parts Part A includes both children and teenagers, while Part B includes only children. Initially, only teenagers meeting specific study rules can join, with children joining after sufficient data is available from other studies. In Part A, participants are randomly assigned to receive either zasocitinib or a matching placebo orally once daily for the first 16 weeks. After this, all receive zasocitinib until the study ends. In Part B, all children receive weight-based oral doses of zasocitinib throughout the study. The treatment lasts up to 208 weeks, with a total study participation time of up to 217 weeks, including screening and safety follow-up. Participants will visit the study site multiple times during the study for assessments, including skin evaluations and measuring drug levels in the blood. Researchers will monitor how well participants respond using various psoriasis severity scales and quality of life questionnaires. A safety follow-up period of 4 weeks occurs after treatment ends to monitor any ongoing effects. The study aims to understand zasocitinibs effects and safety in this young population over a long term.

Age: 4Years - 17YearsAll GendersPhase 3
39 locations
L

Actively Recruiting

Researchers are collecting long-term safety and effectiveness data of unilateral thalamotomy using the Exablate Neuro system for people with medication-refractory tremor dominant Parkinsons Disease TDPD. This observational post-approval registry is required following the approval of the Exablate Model 4000 Type 1.0 and 1.1 devices. The study focuses on patients who have already received this focused ultrasound treatment for tremor associated with TDPD. Participants have undergone unilateral thalamotomy targeting the ventralis medius region using the commercially available Exablate Neuro device. No new interventions are performed during this registry. Data collection includes monitoring medication use and various assessments over time to understand the treatments long-term impact. Participants are followed with assessments at baseline, 1, 3, 6, and 12 months after their procedure, then annually for up to five years. Researchers collect information on adverse events, clinical tremor ratings on medication, Parkinsons motor function, quality of life, and work productivity. The primary outcome is the evaluation of long-term adverse events over five years, alongside measuring tremor and motor symptom impact on disability.

Age: 30Years - 99YearsAll Genders
8 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with cutaneous sarcoidosis, a condition affecting the skin. This phase 23 randomized, double-blind, placebo-controlled trial aims to study different doses of brepocitinib to understand how it impacts the diseases activity and morphology. The study is sponsored by Priovant Therapeutics, Inc. and focuses on measuring adverse events and improvements in skin condition over 16 weeks. Participants will be randomly assigned to receive one of several doses of oral brepocitinib or a placebo. The study is divided into two parts Part 1 compares two dose levels of brepocitinib against placebo, and Part 2 evaluates one dose level against placebo. Treatment lasts for 16 weeks, during which participants take the study drug or placebo orally. The trial uses a triple-blind design, meaning participants, investigators, and others involved do not know which treatment is being given. During the 16-week treatment period, participants will be regularly monitored for treatment-emergent adverse events and serious side effects using CTCAE v5.0 criteria. The main measurement of effectiveness is the reduction in the Cutaneous Sarcoidosis Activity and Morphology Instrument Activity CSAMI-A score from baseline to Week 16. Secondary measures include changes in CSAMI-A scores and the proportion of participants achieving low disease activity. Safety and treatment effects are closely observed, with the study completion planned for the end of 2029.

Age: 18Years +All GendersPhase 2Phase 3
44 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of bimekizumab compared to a placebo in adults with palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This Phase 3 study aims to provide important information about this treatment option in participants who have had PPP for at least 24 weeks and meet specific severity criteria. Participants will be randomly assigned to one of two groups one receiving bimekizumab throughout the study and the other receiving a placebo initially, then switching to bimekizumab during the maintenance phase. The treatments are given at scheduled times, and the study includes an open-label extension period to further assess the treatment. During the study, participants will have regular assessments of their skin condition, including the Palmoplantar Pustulosis-Investigator Global Assessment and Palmoplantar Pustulosis Area Severity Index at weeks 8 and 16. Quality of life and pain levels will also be evaluated. Safety is closely monitored through the recording of any adverse events up to approximately 117 weeks. The total time commitment includes initial treatment and an extended safety follow-up period.

Age: 18Years +All GendersPhase 3
91 locations
E

Actively Recruiting

Researchers are studying severe alopecia areata AA, a condition where the immune system attacks hair follicles causing hair loss on the scalp and face, in pediatric patients aged 6 to under 18 years. The study evaluates the safety and effectiveness of upadacitinib, an investigational Janus-Kinase JAK inhibitor, compared to placebo. This phase 3, randomized, double-blind, placebo-controlled trial addresses the need for systemic treatments approved for young patients, as current options may not work or lose effectiveness over time. Participants are randomly assigned to one of three groups two different doses of upadacitinib or a matching placebo. The study lasts approximately 160 weeks and includes a 35-day screening period, a 24-week placebo-controlled treatment phase Period A, a 28-week blinded extension Period B, a 108-week long-term extension Period C, and a 30-day follow-up. Those initially on placebo who do not achieve sufficient hair regrowth may switch to upadacitinib during the extension periods. During the study, participants attend regular hospital or clinic visits for medical assessments, blood tests, questionnaires, and side effect monitoring. The main outcome measured is the percentage of participants achieving a Severity of Alopecia Tool SALT score indicating 20% or less scalp hair loss at Week 24. Researchers also track adverse events through Week 160 and assess other measures related to hair loss, quality of life, anxiety, and depression. Participants adherence and safety are closely monitored throughout the long study duration.

Age: 6Years - 17YearsAll GendersPhase 3
14 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and effectiveness of Abbott deep brain stimulation DBS systems used for various movement disorders, including Parkinsons disease, essential tremor, disabling tremor, and dystonia. This international, prospective, multicenter study collects data from patients implanted with Abbott DBS devices during routine clinical care to understand outcomes over time. Participants implanted with the Abbott DBS system will be observed without altering their treatment, as this is an observational study. The study follows subjects for five years from their initial programming visit to gather information on device performance and patient motor function over time. During the study, participants will have regular assessments using disease-specific motor rating scales such as MDS-UPDRS Part III for Parkinsons disease and FTM-TRS for tremor. Researchers will monitor changes in motor symptoms and record any serious device- or procedure-related adverse events. Study involvement lasts for five years, allowing long-term collection of safety and effectiveness data.

All AgesAll Genders
48 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating how skin from night shift workers responds to artificial sunlight, specifically ultraviolet B radiation UVB, compared to skin from normal day shift workers. The study focuses on measuring DNA repair activity and gene expression related to skin damage and repair mechanisms in individuals with different work schedules. This pilot study aims to better understand potential differences in skin responses that might relate to skin cancer risks among these groups. Participants will have a small skin punch biopsy taken, which will then be exposed in the laboratory to UVB radiation or kept as a non-irradiated control. The study includes two groups based on work schedule day shift workers and night shift workers. The biopsies are incubated for one hour after UVB exposure before further analysis. Both groups undergo the same laboratory procedures to compare skin responses under controlled conditions. During the study, participants will provide information about their work schedules for the past three months and confirm their skin type and health status. Researchers will assess several primary outcomes including the expression level of the DNA repair factor XPA, core clock gene expression, nucleotide excision repair activity, and activation of DNA damage signaling pathways in the skin after UVB exposure. The total participation period is not explicitly stated but involves biopsy collection and laboratory analysis, with safety screening to exclude those with photosensitivity or other health issues.

Age: 18Years - 40YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Rosacea is a common skin condition that causes easy blushing and redness, often worsened by sunlight exposure. Researchers are studying whether topical medications can reduce this sunlight-induced redness and irritation in people with rosacea. This Phase 2 trial aims to evaluate the effects of two topical drugs, imipramine and amitriptyline, on skin redness caused by ultraviolet B UVB light. Participants apply either 4% imipramine or 4% amitriptyline on a small area 2x2 cm of one cheek, while a vehicle control substance is applied on the other cheek. There are two experimental groups one receiving imipramine and vehicle, and the other receiving amitriptyline and vehicle. The treatments are applied directly to the skin, allowing comparison of redness on treated versus untreated areas. During the study, redness levels caused by UVB light will be measured at 10 minutes, 60 minutes, 120 minutes, and 24 hours after treatment application. Researchers will also monitor how well the skin tolerates each medication over these same time points. Participants may be monitored over several visits to assess skin reactions and medication effects. The trial is randomized and double-blind, ensuring unbiased evaluation of the treatments impact on sunlight-induced redness in rosacea.

Age: 18Years +All GendersPhase 2
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are exploring how artificial sunlight, specifically ultraviolet B radiation UVB, affects the skin of young adults compared to older adults. The study focuses on understanding why skin cancer is more common in older skin, which may be due to differences in a protein called insulin-like growth factor-1 IGF-1. Young skin has higher levels of IGF-1, while geriatric skin has very little. This research aims to see if injecting IGF-1 into older skin can make it respond more like young skin when exposed to UVB. Participants will have small skin areas exposed to UVB to study the skins reaction. Some areas will receive injections of IGF-1, while others will get saline injections as a comparison. After injection, these areas will also be treated with UVB to observe changes. This study includes young adults and geriatric adults and compares their skin responses with or without IGF-1 treatment. During the study, researchers will monitor gene expression changes that protect skin cells from UVB damage, measured two days after treatment. Participants skin responses will be closely examined to understand the effects of IGF-1 injection. The study involves no blinding or randomization, and healthy volunteers with specific skin types and ages will be enrolled. The total duration for assessing the primary outcome is two days post-treatment.

Age: 21Years +All GendersEarly Phase 1
1 location
L

Actively Recruiting

Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.

Age: 40Years +All GendersPhase 3
411 locations

1-10 of 16

1